Now showing items 325-344 of 4640

    • Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping 

      Schwartz, GF; Bartelink, H; Burstein, HJ; Cady, B; Cataliotti, L; Fentiman, IS; Holland, R; Hughes, KS; Masood, S; McCormick, B; Palazzo, JA; Pressman, PI; Reis-Filho, J; Pusztai, L; Rutgers, EJT; Seidman, AD; Solin, LJ; Sparano, JA
      A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, ...
    • Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. 

      Husson, O; Prins, JB; Kaal, SEJ; Oerlemans, S; Stevens, WB; Zebrack, B; van der Graaf, WTA; van de Poll-Franse, LV (2017-02)
      Background Trying to simultaneously achieve developmental milestones and cope with a life-threatening disease may place adolescents and young adults (AYAs) at risk for impaired health-related quality of life (HRQoL) later ...
    • Adolescent’s stress responses and psychological functioning when a parent has early breast cancer 

      Edwards, L; Watson, M; James-Roberts, IS; Ashley, S; Tilney, C; Brougham, B; Osborn, T; Baldus, C; Romer, G (JOHN WILEY & SONS LTD, 2008-10)
      Objective: To identify factors associated with psychological functioning in adolescent children of early-stage breast cancer patients. Method. Adolescents’ self-reported psychological functioning using the Child Behaviour ...
    • ADP-ribosyltransferases, an update on function and nomenclature. 

      Lüscher, B; Ahel, I; Altmeyer, M; Ashworth, A; Bai, P; Chang, P; Cohen, M; Corda, D; Dantzer, F; Daugherty, MD; Dawson, TM; Dawson, VL; Deindl, S; Fehr, AR; Feijs, KLH; Filippov, DV; Gagné, J-P; Grimaldi, G; Guettler, S; Hoch, NC; Hottiger, MO; Korn, P; Kraus, WL; Ladurner, A; Lehtiö, L; Leung, AKL; Lord, CJ; Mangerich, A; Matic, I; Matthews, J; Moldovan, G-L; Moss, J; Natoli, G; Nielsen, ML; Niepel, M; Nolte, F; Pascal, J; Paschal, BM; Pawłowski, K; Poirier, GG; Smith, S; Timinszky, G; Wang, Z-Q; Yélamos, J; Yu, X; Zaja, R; Ziegler, M (2021-07-29)
      ADP-ribosylation, a modification of proteins, nucleic acids, and metabolites, confers broad functions, including roles in stress responses elicited, for example, by DNA damage and viral infection and is involved in intra- ...
    • Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. 

      Chamberlain, F; Cojocaru, E; Scaranti, M; Noujaim, J; Constantinou, A; Thway, K; Fisher, C; Messiou, C; Strauss, DC; Miah, A; Zaidi, S; Benson, C; Gennatas, S; Jones, RL (2019-12-27)
      Soft tissue myoepithelial carcinomas are a rare, malignant subgroup of myoepithelial tumours mostly arising in the extremities with equal predilection for women and men. The mainstay of management of localised disease is ...
    • Adult T-cell leukaemia/lymphoma 

      Matutes, E (B M J PUBLISHING GROUP, 2007-12)
      Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution. The disease ...
    • Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. 

      Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Chen, Y; Connor, AE; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Larsson, SC; Linet, M; Ma, H; Milne, RL; Ozasa, K; Palmer, JR; Riboli, E; Rohan, TE; Sacerdote, C; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2020-09)
      Early-adulthood body size is strongly inversely associated with risk of premenopausal breast cancer. It is unclear whether subsequent changes in weight affect risk. We pooled individual-level data from 17 prospective studies ...
    • Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. 

      Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; Yuan, W; Athie, A; Casals, T; Carmichael, J; Rodrigues, DN; Gurel, B; Rescigno, P; Rekowski, J; Welti, J; Riisnaes, R; Gil, V; Ning, J; Wagner, V; Casanova-Salas, I; Cordoba, S; Castro, N; Fenor de la Maza, MD; Seed, G; Chandran, K; Ferreira, A; Figueiredo, I; Bertan, C; Bianchini, D; Aversa, C; Paschalis, A; Gonzalez, M; Morales-Barrera, R; Suarez, C; Carles, J; Swain, A; Sharp, A; Gil, J; Serra, V; Lord, C; Carreira, S; Mateo, J; de Bono, JS (2020-11-08)
      Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond.Objective To characterise ATM-deficient ...
    • Advanced roles in cancer nursing 

      Percival, N (Mark Allen Group, 2017-05-25)
    • Advances and challenges in targeting FGFR signalling in cancer. 

      Babina, IS; Turner, NC (2017-05)
      Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential ...
    • Advances in mass spectrometry based strategies to study receptor tyrosine kinases. 

      Vyse, S; Desmond, H; Huang, PH (2017-03)
      Receptor tyrosine kinases (RTKs) are key transmembrane environmental sensors that are capable of transmitting extracellular information into phenotypic responses, including cell proliferation, survival and metabolism. ...
    • Advances in targeted alpha therapy for prostate cancer. 

      De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; O'Sullivan, JM; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O; Targeted Alpha Therapy Prostate Working Group
      Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing ...
    • Advances in targeted alpha therapy for prostate cancer. 

      De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; O'Sullivan, JM; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O; Targeted Alpha Therapy Prostate Working Group (2019-11)
      Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing ...
    • Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. 

      Dolly, SO; Collins, DC; Sundar, R; Popat, S; Yap, TA (2017-05)
      Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality. The traditional 'one-size-fits-all' treatment approach has now evolved into one that ...
    • Advances in the Pathology and Molecular Biology of Sarcomas and the Impact on Treatment. 

      Thway, K; Noujaim, J; Jones, RL; Fisher, C (2017-08)
      Sarcomas are a complex group of childhood and adult neoplasms with differentiation towards mesenchymal tissues that can occur at almost every anatomic site. Although pathologically diverse, they frequently show similar ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • Advances in the treatment of gastrointestinal stromal tumours. 

      Judson, I; Demetri, G (2007-09)
      Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease ...
    • Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. 

      Moreau, P; Dimopoulos, MA; Richardson, PG; Siegel, DS; Cavo, M; Corradini, P; Weisel, K; Delforge, M; O'Gorman, P; Song, K; Chen, C; Bahlis, N; Oriol, A; Hansson, M; Kaiser, M; Anttila, P; Raymakers, R; Joao, C; Cook, G; Sternas, L; Biyukov, T; Slaughter, A; Hong, K; Herring, J; Yu, X; Zaki, M; San-Miguel, J (2017-09)
      Objectives Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to ...
    • Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. 

      Kaiser, M; Beksaç, M; Gulbrandsen, N; Schjesvold, F; Hájek, R; Moreau, P; de Arriba de la Fuente, F; Mateos, M-V; West, S; Spencer, A; Rajkumar, SV; Suryanarayan, K; Czorniak, M; Li, C; Teng, Z; Labotka, R; Dimopoulos, MA (2020-08)
      The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in ...